Find Iobenguane manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 87862-25-7, Mibg, Iobenguane sulphate, M-iodobenzylguanidine hemisulfate, M-iodobenzyl guanidine sulfate, 1-(3-iodobenzyl)guanidine hemisulfate
Molecular Formula
C16H22I2N6O4S
Molecular Weight
648.3  g/mol
InChI Key
XNACDNPGABUBFR-UHFFFAOYSA-N
FDA UNII
S8I0922465

Iobenguane
A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
1 2D Structure

Iobenguane

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(3-iodophenyl)methyl]guanidine;sulfuric acid
2.1.2 InChI
InChI=1S/2C8H10IN3.H2O4S/c2*9-7-3-1-2-6(4-7)5-12-8(10)11;1-5(2,3)4/h2*1-4H,5H2,(H4,10,11,12);(H2,1,2,3,4)
2.1.3 InChI Key
XNACDNPGABUBFR-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=CC(=C1)I)CN=C(N)N.C1=CC(=CC(=C1)I)CN=C(N)N.OS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
S8I0922465
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3-iodo-(131i)benzyl)guanidine

2. 123i Labeled 3-iodobenzylguanidine

3. 125i Labeled 3-iodobenzylguanidine

4. 3 Iodobenzylguanidine

5. 3 Iodobenzylguanidine, 123i Labeled

6. 3 Iodobenzylguanidine, 125i Labeled

7. 3-iodobenzylguanidine

8. 3-iodobenzylguanidine, 123i Labeled

9. 3-iodobenzylguanidine, 125i Labeled

10. Iobenguane

11. Iobenguane (131i)

12. M Iodobenzylguanidine

13. M-iodobenzylguanidine

14. Meta Iodobenzylguanidine

15. Meta-iodobenzylguanidine

16. Mibg

2.3.2 Depositor-Supplied Synonyms

1. 87862-25-7

2. Mibg

3. Iobenguane Sulphate

4. M-iodobenzylguanidine Hemisulfate

5. M-iodobenzyl Guanidine Sulfate

6. 1-(3-iodobenzyl)guanidine Hemisulfate

7. Mibg (sulfate)

8. 3-iodobenzyl-guanidine Sulfate

9. M-iodobenzyl Guanidine Sulphate

10. 3-iodobenzyl-guanidine Sulphate

11. Iobenguane (sulfate)

12. Guanidine, N-((3-iodophenyl)methyl)-, Sulfate (2:1)

13. M-idobenzyl Guanidine Sulfate [vandf]

14. Guanidine, [(3-iodophenyl)methyl]-, Sulfate (2:1)

15. M-iodobenzylguanidine Hemisulfate Salt

16. Mibg Hemisulfate

17. Ncgc00094011-01

18. S8i0922465

19. Dsstox_cid_25773

20. Dsstox_rid_81115

21. Dsstox_gsid_45773

22. 3-iodobenzylguanidine Hemisulfate

23. Cas-87862-25-7

24. Ncgc00015572-04

25. Eu-0100644

26. 1-(3-iodobenzyl)guanidine Hcl

27. Chembl1374843

28. 3-iodobenzylguanidine Hemisulphate

29. 3-iodobenzyl-guanidine Hemisulfate

30. Hms3262a09

31. Unii-s8i0922465

32. Tox21_111237

33. Tox21_113518

34. Tox21_500644

35. 1-(3-iodobenzyl)guanidinehemisulfate

36. Akos015996512

37. Meta-iodobenzylguanidine Sulfate

38. Ccg-221948

39. Lp00644

40. Ncgc00261329-01

41. Bs-45793

42. E74924

43. I 9890

44. 2-[(3-iodophenyl)methyl]guanidine; Sulfuric Acid

45. A839961

46. 2-[(3-iodanylphenyl)methyl]guanidine; Sulfuric Acid

47. Q27289056

48. M-iodobenzylguanidine Hemisulfate Salt, >=98% (hplc And Tlc)

49. 3-iodobenzyl-guanidine Hemisulfate 103346-16-3 80663-96-3

50. Iobenguane Sulfate, European Pharmacopoeia (ep) Reference Standard

51. 80663-96-3

2.4 Create Date
2006-12-01
3 Chemical and Physical Properties
Molecular Weight 648.3 g/mol
Molecular Formula C16H22I2N6O4S
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass647.95127 g/mol
Monoisotopic Mass647.95127 g/mol
Topological Polar Surface Area212 Ų
Heavy Atom Count29
Formal Charge0
Complexity247
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


Radiopharmaceuticals

Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)


API SUPPLIERS

read-more
read-more

01

ABX Advanced Biochemical Compounds

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

ABX Advanced Biochemical Compounds

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed

01

Pharma, Lab & Chemical Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21543

Submission : 2008-04-18

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20210322005101/en/Lantheus-Announces-Presentation-Featuring-AZEDRA%C2%AE-iobenguane-I-131-at-ENDO-2021#:~:text=Business%20Wire-,Lantheus%20Announces%20Presentation%20Featuring%20AZEDRA%C2%AE,I%20131)%20at%20ENDO%202021&text=NORTH%20BILLERICA%2C%20Mass.%2D%2D(BUSINESS,WIRE)%2D%2DLantheus%20Holdings%2C%20Inc.&text=%E2%80%9CAZEDRA%20is%20the%20first%20and,Chief%20Medical%20Officer%20of%20Lantheus.

BUSINESSWIRE
22 Mar 2021

https://www.fiercebiotech.com/medtech/lantheus-to-buy-progenics-to-chase-both-cancer-imaging-diagnostics-and-therapeutics

Conor Hale FIERCE BIOTECH
03 Oct 2019

https://www.reuters.com/article/us-progenics-pharm-fda/fda-approves-progenics-treatment-for-rare-adrenal-gland-tumors-idUSKBN1KK2C2

Manas Mishra REUTERS
31 Jul 2018

https://www.biospace.com/article/fda-approves-progenics-pharma-s-azedra-for-ultra-rare-cancers/

Mark Terry BIOSPACE
31 Jul 2018

https://globenewswire.com/news-release/2018/07/31/1544259/0/en/Progenics-Pharmaceuticals-Announces-FDA-Approval-for-AZEDRA-iobenguane-I-131-to-Treat-Unresectable-Locally-Advanced-or-Metastatic-Pheochromocytoma-or-Paraganglioma.html

GLOBENEWSWIRE
31 Jul 2018
FDA approves first drug to treat rare adrenal cancer
FDA approves first drug to treat rare adrenal cancer

31 Jul 2018

// Joy Persaud PHARMAPHORUM

https://pharmaphorum.com/cancer/fda-approves-first-drug-to-treat-rare-adrenal-cancer/

Joy Persaud PHARMAPHORUM
31 Jul 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty